The Michigan Medicine Department of Radiation Oncology is a worldwide leader in cancer treatment and research. The novel research studies and clinical trials conducted by our faculty drives discovery and advances our cancer treatment delivery and effectiveness.
To learn more about the studies in Radiation Oncology listed below, please email Jody Sharp or phone 734-615-4909.
Questions about cancer treatment at Michigan Medicine can also be addressed at the Rogel Cancer Center AnswerLine: (800) 865-1125. To learn more about open clinical trials throughout the Michigan Medicine enterprise, search the Rogel Cancer Center's clinical trials directory. For Oncology-specific trials, go to the Rogel Cancer Center's Oncology Clinical Trials listing.
Highlights


List of Trials
Metastases
UMCC 2018.032: 9979 / HP-00067789: Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
Brain
UMCC 2017.094: A Prospective Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
RTOG 1071 / ALLIANCE N0577: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma (Alliance N0577)
Head & Neck
UMCC 2018.085: Phase II Trial Of Radiotherapy, Carboplatin/Paclitaxel And Nivolumab For High Risk HPV-Related Oropharynx Cancer
UMCC 2018.070: The feasibility of evaluating cervical, thoracic, and scapular dysfunction in head and neck cancer patients
UMCC 2017.113: A Phase II Trial of Individualized Adaptive De-Escalated Radiotherapy Using Pre- and Mid-Treatment FDG-PET/CT for HPV-Related Oropharynx Cancer
UMCC 2013.062: Randomized Phase II study of DCE-MRI-based dose escalation for poor-prognosis head and neck cancer
NRG-HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Breast
MA.39: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory Breast Cancer
Lung/Thoracic
UMCC 2018.121: The Selective Personalized Radio-Immunotherapy for locally advanced NSCLC Trial (SPRINT)
Liver/GI
UMCC 2015.039: A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
UMCC 2003.081: Assessment of Liver Function in Patients Undergoing Hepatic Irradiation
UMCC 2006.067: A Pilot Study of Radiation Toxicity Using MRI-Based Perfusion.
HUM00133653: A Study of Circulating Biomarkers in Hepatocellular Carcinoma
Prostate/GU
UMCC 2018.084: Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): a phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) w/wo neurovascular sparing for erectile function preservation in localized PC
UMCC 2017.156: Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide
NRG-GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer
NRG-GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
GYN
New NRG Study Coming Soon!
Other
UMCC 2012.113: Optimization of MRI for Radiation Therapy
VA Trials
Chapman IRB-2016-353: Randomized Phase II Study of DCE-MRI Based Dose Escalation for Poor-Prognosis Head and Neck Cancer (UMCC 2013.062)
Elliott IRB-2015-350: A Pilot Study of Response-Driven Adaptive Radiation Therapy For Patients with Locally Advanced NSCLCa (UMCC 2015.035)
Chapman IRB-2018-1090: A Multi-Center Phase II Trial of Individualized Adaptive De-Escalated Radiotherapy Using Pre- and Mid-Treatment FDG-PET/CT for HPV-Related Oropharynx Cancer (UMCC 2017.113)
Brighton Center for Specialty Care Trials
UMCC 2017.156: Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide
NRG-GU006: A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer
UMCC 2018.084: Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): a phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) w/wo neurovascular sparing for erectile function preservation in localized PC
S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory Breast Cancer
UMCC 2017.113: A Phase II Trial of Individualized Adaptive De-Escalated Radiotherapy Using Pre- and Mid-Treatment FDG-PET/CT for HPV-Related Oropharynx Cancer